Sparsentan, a medication, may be a potential new treatment option for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder that can lead to kidney failure. A University of Minnesota Medical School-led study found that FSGS patients treated with sparsentan showed improved kidney function and displayed significant reductions in proteinuria.
Data breach hits Blue Shield of California vendor
Blue Shield of California members may have had their data exposed in a November data breach. Information included member names, dates of birth, addresses, subscriber
